rimonabant

(redirected from Acomplia)

rimonabant

A selective cannabinoid-1 receptor blocker that has been shown to reduce body weight and the risk of cardiovascular disease in obese people. The drug has been shown capable of achieving substantial weight loss and reducing cardiovascular risk factors. It has aroused excitement among drug manufacturers who hope it may prove effective in the control of smoking as well as excessive calorie and alcohol intake.
References in periodicals archive ?
Drug Trade Name Mode of Action Orlistat Xenical Lipase inhibitor Orlistat Alli (OTC) Lipase inhibitor Phentermine Duromine, NA/DA releasing Ionamin agent Methamphetamine Desoxyn NA/DA releasing agent Benzphentamine Didrex Sympathomimetic Phendimetrazine Bontril Sympathomimetic Diethylpropion Apisate, Sympathomimetic (amfepramone) Tenuate Sibutramine Reductil, NA/5-HT re-uptake Meridia inhibitor Rimonabant Acomplia [CB.
Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use.
Three years ago, 23- year- old Neha ( name changed) convinced her mother that a mild dose of Rimoslim, also known as Acomplia or Rimonabant, would help her drop a dress size.
For example, the Acomplia created by Sanofi-Aventis was withdrawn from the market in September 2008, though its AMM only dated from June 2006.
Repeated FDA Delays, European Restrictions Ail Sanofi's Acomplia Wingfield N Jobs Helped Pick 'Favorable' Dates for Option Grants Wysocki B Private Practice: Is U.
unanimously not to recommend a weight-loss treatment called Acomplia.
The two leading drugs in the market Acomplia (rimonabant; sanofi-aventis) and Meridia (sibutramine; Abbott Laboratories) have both been withdrawn from the European markets because of side effects, and Acomplia has never received regulatory approval in the United States.
Segundo Bertuol e Budel (2008) em 24 de outubro de 2008, sua venda foi suspensa, temporariamente, em todo o mundo e, a partir de 28 de outubro de 2008, a Sanofi-Aventis decidiu retirar do mercado o medicamento Acomplia (rimonabanto).
The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia.
The researchers found no studies that met their criteria for patients who took rimonabant, known by the brand name Acomplia.
Sanofi failed in its attempt to have the Acomplia obesity drug approved by the FDA in 2007.